Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.80 |
| ▸ | TSHR | P16473 | 4/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.75 |
| ▸ | RAB9A | P51151 | 3/20 | 0.75 |
| ▸ | NPC1 | O15118 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | MAOA | P21397 | 2/20 | 0.72 |
| ▸ | ESR1 | P03372 | 2/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.70 |
| ▸ | KDR | P35968 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.68 |
| ▸ | HTR3A | P46098 | 1/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Risocaine SCHEMBL10481404 | 0.98 | LMNA (0.77) | LMNACYP1A2TSHRCYP3A4CYP2C19 | |
| Risocaine SCHEMBL21873190 | 0.98 | LMNA (0.77) | LMNACYP1A2TSHRCYP3A4CYP2C19 | |
| Risocaine SCHEMBL21647391 | 0.96 | LMNA (0.75) | LMNACYP1A2TSHRCYP3A4CYP2C19 | |
| SCHEMBL49950 | 0.90 | ALDH1A1 (0.84) | LMNACYP1A2TSHRCYP3A4CYP2C19 | |
| Butamben SCHEMBL81735 | 0.89 | LMNA (1.00) | LMNACYP1A2TSHRCYP3A4CYP2C19 | |
| SCHEMBL28758641 | 0.88 | ALDH1A1 (0.81) | LMNACYP1A2TSHRCYP3A4CYP2C19 | |
| SCHEMBL27647586 | 0.88 | ALDH1A1 (0.81) | LMNACYP1A2TSHRCYP3A4CYP2C19 | |
| SCHEMBL27667930 | 0.88 | ALDH1A1 (0.81) | LMNACYP1A2TSHRCYP3A4CYP2C19 | |
| SCHEMBL27647510 | 0.88 | ALDH1A1 (0.81) | LMNACYP1A2TSHRCYP3A4CYP2C19 | |
| SCHEMBL27667922 | 0.88 | ALDH1A1 (0.81) | LMNACYP1A2TSHRCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1812 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144801-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-28 | — | — | US | claimed |
| WO-2025235864-A1 | COATED NEEDLE ADMINISTRATION SYSTEMS | EVOLUS, INC. (US) | 2025-11-13 | — | — | WO | claimed |
| EP-4578441-A1 | TREATMENT OF LOCALIZED PAIN | PlantTec Medical GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| CN-119925187-A | Oral care composition and method for maintaining oral hygiene using the same | 进化牙白金有限公司 | 2025-05-06 | — | — | CN | claimed |
| WO-2025085689-A1 | EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-24 | — | — | WO | claimed |
| EP-3703802-B9 | NASAL DELIVERY DEVICES AND METHODS OF USE THEREOF | CLEXIO BIOSCIENCES LTD (IL) | 2024-12-04 | — | — | EP | claimed |
| EP-3703802-B1 | NASAL DELIVERY DEVICES AND METHODS OF USE THEREOF | CLEXIO BIOSCIENCES LTD (IL) | 2024-10-16 | — | — | EP | claimed |
| EP-3863708-B1 | MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING | BATTELLE MEMORIAL INSTITUTE (US) | 2024-09-11 | — | — | EP | claimed |
| US-20240197867-A1 | NEURAL CONTROL OF ADAPTIVE IMMUNITY | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2024-06-20 | — | — | US | claimed |
| US-20240165247-A1 | NEW PEPTIDE CONJUGATES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-05-23 | — | — | US | claimed |
| US-20010055607-A1 | COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES | BHL PATENT HOLDINGS LLC | 2001-12-27 | — | — | US | claimed |
| US-20010004644-A1 | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation | LEVIN BRUCE H (US) | 2001-06-21 | — | — | US | claimed |
| WO-2001043733-A2 | COMPOSITIONS, KITS, APPARATUS, AND METHODS FOR INHIBITING CEPHALIC INFLAMMATION | LEVIN BRUCE H (US) | 2001-06-21 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-6207178-B1 | STABLE SUSPENSION | KABI PHARMACIA AB (SE) | 2001-03-27 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5785976-A | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof | PHARMACIA & UPJOHN AB (SE) | 1998-07-28 | — | — | US | claimed |
| EP-0687172-A1 | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF | Pharmacia & Upjohn Aktiebolag (SE) | 1995-12-20 | — | — | EP | claimed |
| WO-1994020072-A1 | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF | PHARMACIA AB (SE) | 1994-09-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010055607-A1 | COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES | TNNC1, KIT, PDE3A | LMNA 477/4885CYP1A2 2135/4885TSHR 4600/4885 |
| US-20010004644-A1 | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation | CXCR5, CCL5, C5AR2 | LMNA 1480/4885CYP1A2 1652/4885TSHR 4356/4885 |
| US-20240197867-A1 | NEURAL CONTROL OF ADAPTIVE IMMUNITY | TRPV1, TRPA1, TRPV2 | LMNA 4746/4885CYP1A2 4785/4885TSHR 3276/4885 |
| US-20260144801-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS | CPT1B, HPGD, PTGES | LMNA 1427/4885CYP1A2 360/4885TSHR 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.